Affordability At Cost Of Innovation?

Friday, March 10, 2017 General News
Email Print This Page Comment
Font : A-A+

In a major relief to coronary heart disease patients in India the government earlier this month imposed a ceiling on the prices of coronary stents. Accordingly the price of bare metal stents was brought down to Rs 7260 from Rs 45000 and that of drug-eluting
stents to Rs 29600 from about Rs 1.2 lakh. For the technically-minded a coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart in order to keep the arteries open during treatment of coronary heart disease.
It is used in a procedure known as percutaneous coronary intervention (PCI). As expected the move by the government drew reactions ranging from relief to shock. Patients and their family members were expectedly relieved while hospitals retailers and wholesales cried blue murder. According to a research paper published in The Lancet in December 2015 about two-thirds of the expenses incurred by patients/family members out of their personal resources on health-related issues went for the purchase of drugs pointing to unnecessary use of high-cost medical technologies such as stents and knee implants. That these technologies were pushed to maximise sales is an open secret. Therefore a cap on their prices would surely help patients. The governments move saw the pharmaceutical companies manufacturing absorbable stents withdrawing their stocks and consequently refusing to supply them at the price set by the National Pharmaceutical Pricing Authority (NPPA). Hospitals complain that it has put them in bad light. There is a feeling among doctors that the government should have foreseen this predicament and made available good quality stents in ample numbers before capping the price. They fear the move will give rise to black-marketing of stents. For they argue the well-heeled will always be willing to pay whatever price for the latest stents. "When any product is made unavailable it naturally creates a ready market for black marketers. This is replete in history. I fear this will be repeated in Indias stent market too" said one doctor who refused to be named. It would be wrong to say the government did not expect to see a sharp reaction from pharmaceutical companies manufacturing these stents. That is why the government has invoked the emergency provision making it mandatory for manufacturers of stents to maintain production and supply of coronary stents at previous levels for six months at least. Also stent-makers and importers have been told to submit a weekly report on production and distribution levels to the drug price regulator NPPA. However multinational companies manufacturing stents say the prices mandated by the NPPA are unrealistic and would hurt research and development (R&D). And without R&D it would be impossible to roll-out devices using cutting-edge technology in India. This being a capital-intensive industry segment and the cost of working capital in India being high prices will remain elevated in order to be able to remunerate all stakeholders argue those on the side of the stent-makers. "Research and development in the pharmaceutical industry is a very high-cost activity. It has its pitfalls in the form of many products falling by the wayside before one successfully hitting the market. So the innovators/ inventors need to be adequately rewarded for the risk taken. In the stents market there is continuous innovation rendering the process and the product expensive. Moreover stocking these products entail a lot of capital deployment. Who will foot the bill for all this? The government should have thought through all these angles before taking this step. Agreed pricing is high and patients are strained having to foot these bills. Yet instead of painting everyone with the same brush they should have taken steps to curtail profiteering. They should have taken the stakeholders into confidence. Medical insurance should be pushed in the same way digital currency is being pushed by the government so that medical costs are met by insurance companies and not by patients" argues an expert upset at the turn of events. While a section of the experts say the move will force stent-makers to innovate to keep prices in check others say government intervention in pricing (and thus not permitting free-market to function in the country) will hurt innovation and in turn the governments Make in India initiative. They even argue that with high-quality stents being not readily available in the Indian market medical tourism will take a hit. "Why should patients looking for heart treatment come to India in the midst of uncertainty surrounding availability of quality stents when they can go to say Malaysia or Singapore and get the same treatment albeit at a little higher cost? This move will buffet Indias medical tourism industry no doubt" said another doctor on condition of anonymity. For now the jury is out on the merits of the case. And the tug-of-war between the government and stents-makers/ sellers could get tougher. One way out though a little long-term in nature would be make medical insurance mandatory for all in the country. But wouldnt that be tough to achieve in India where the penetration of health insurance is not that satisfactory? Not if one looks at the zeal with which the government forced the people to adopt digital currency and give up the use of cash in everyday dealings.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook